Advertisement

Methods for the Use of Cytokine Gene-Modified Tumor Cells in Immunotherapy of Cancer

  • Zhihai Qin
  • Thomas Blankenstein
Part of the Methods in Molecular Medicine book series (MIMM, volume 7)

Abstract

The development over the past few years has shown that gene therapy has become a true perspective. By January 1994, 63 clinical gene therapy protocols (gene therapy or marker studies) have been reviewed and most approved by U.S. control committees. Of these, 13 aim at inserting and expressing cytokine genes in tumor cells in order to use such gene-modified cells as vaccines in cancer patients, This idea is based on mouse experimental models that showed that tumor cells transfected with a variety of cytokine genes were rejected in immunocompetent animals. Tumor rejection induced by the locally produced cytokine results from an inflammatory response at the tumor site. Several observations are remarkable: the high efficacy of local cytokines to induce an antitumor response in the absence of systemic toxicity; a surprisingly large number of cytokines possess antitumor activity in this assay (IL-1, IL-2, IL-4, IL-6, IL-7, TNF, LT, IFN-γ, MCAF, G-CSF, GM-CSF, IP-10); and in several models, cytokine-producing tumors were heavily infiltrated by T-lymphocytes that contributed to tumor destruction (for review see ref. 1). The latter observation is interesting because T-cells can most specifically recognize and destroy tumor cells and are critically involved in tumor immunity Consistently, in several tumor models, mice that were immunized by cytokine-gene transfected tumors also rejected the nontransduced parental tumor and occasionally were able to eliminate small preexisting tumor loads. Tumor immunity was dependent on T-cells. Thus, cytokine gene-modified tumor cell vaccines are thought to trigger a local immune response in cancer patients, which is directed against putative, so far unknown tumor antigens and which are effective against residual (presumably small) tumor loads (e.g., micrometastasis). It is important to note that these genetic approaches to cancer immunotherapy are the beginning of a developing field and still have to address some unresolved problems such as inappropriate presentation of tumor antigens by the tumor cells, tumor-induced immune suppression, tumor heterogeneity, or the question as to whether they are more effective than the previous attempts of immunotherapy. Currently, three cytokine gene therapy variations with IL-2, IL-4, TNF, IFN-γ, or GM-CSF genes are tested: transfected autologous tumor cells; transfected allogeneic tumor cells; and transfected autologous fibroblasts mixed with tumor cells as vaccine. In most cases, the cells are irradiated before injection. Results from these initial clinical trials do not exist yet.

Keywords

Cytokine Gene Tumor Immunity Syngeneic Mouse Crystal Violet Solution Inject Tumor Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Blankenstein, T. (1994) Increasing tumor immunogenicity by genetic modification. Eur J Cancer 30A, 1182–1187.PubMedCrossRefGoogle Scholar
  2. 2.
    Colombo, M. P. and Forni, G. (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15, 48–51.PubMedCrossRefGoogle Scholar
  3. 3.
    Gillis, S., Ferm, M. M., Ou, W, and Smith, K. A. (1978) T cell growth factor: parameters of production and a quantitative microassay for activity J. Immunol. 120, 2027–2032.PubMedGoogle Scholar
  4. 4.
    Palacios, R. and Steimnetz, M. (1985) IL-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41, 727–734.PubMedCrossRefGoogle Scholar
  5. 5.
    Hu-Li, J., Ohara, J., Watson, C., Tsang, W., and Paul, W. E. (1989) Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S) J. Immunol. 142, 800–807.PubMedGoogle Scholar
  6. 6.
    Rolink, A. G., Melchers, F., and Palacios, R. (1989) Monoclonal antibodies reactive with the mouse interleukin 5 receptor. J. Exp Med 169, 1693–1701.PubMedCrossRefGoogle Scholar
  7. 7.
    Van Snick, J., Vink, A., Cayphas, S., and Uyttenhove, C.(1987) Interleukin-HP1, a T cell derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas. J Exp Med. 165, 641–649.PubMedCrossRefGoogle Scholar
  8. 8.
    Park, L. S., Friend, D. J., Schmierer, A. E, Dower, S. K., and Namen, A. E. (1990) Murine interleukin 7 (IL-7) receptor. Characterization on an IL-7-dependent cell line J Exp. Med 171, 1073–1089.PubMedCrossRefGoogle Scholar
  9. 9.
    Dexter, T. M., Garland, J., Scott, D., Scolnick, E., and Metcalf, D (1980) Growth of factor-dependent hemopoietic precursor cell lines. J Exp. Med. 152, 1036–1047.PubMedCrossRefGoogle Scholar
  10. 10.
    Flick, D. A. and Gifford, G. E. (1984) Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol. Meth. 68, 167.CrossRefGoogle Scholar
  11. 11.
    Coligan, J. E., et al. (1992) Current Protocols in Immunology (Coligan, J. E., Kruisbeek, A. M., Marguhes, D. H., Sherach, E. M., and Strober, W., eds), Greene and Wiley, New York, pp. 6.8.3.Google Scholar
  12. 12.
    Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colonystimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539–3543.PubMedCrossRefGoogle Scholar
  13. 13.
    Hock, H., Dorsch, M., Kunzendorf, U., Uberla, K., Qin, Z., Diamantstein, T., and Blankenstein, T. (1993) Vaccination with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res. 53, 714–716.PubMedGoogle Scholar
  14. 14.
    Hock, H., Dorsch, M., Kunzendorf, U., Qin, Z., Diamantstein, T, Blankenstein, T. (1993) Mechanisms of rejection induced by tumor cell targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor or interferon-. Proc. Natl Acad. Sci. USA 90, 2774–2778.PubMedCrossRefGoogle Scholar
  15. 15.
    Qin, Z., Krüger-Krasagakes, S., Kunzendorf, U., Hock, H., Diamantstein, T,, and Blankenstein, T. (1993) Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J. Exp Med 178, 355–360.PubMedCrossRefGoogle Scholar
  16. 16.
    Li, W., Diamantstein, T., and Blankenstein, T. (1990) Lack of tumorigenicity of interleukin 4 autocrme growing cells seems related to the anti-tumor function of interleukin 4. Mol. Immunol 27, 1331–1337.PubMedCrossRefGoogle Scholar
  17. 17.
    Blankenstein, T., Qin, Z., Uberla, K., Muller, W., Rosen, H., Volk, H.-D., and Diamantstein, T (1991) Tumor suppression after tumor cell targeted tumor necrosis factor alpha gene transfer, J, Exp Med. 173, 1047–1052CrossRefGoogle Scholar
  18. 18.
    Hock, H., Dorsch, M., Diamantstein, T., and Blankenstein, T (1991) Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med. 174, 1291–1298PubMedCrossRefGoogle Scholar
  19. 19.
    Dye, E. S, North, R J., and Mills, C D. (1981) Mechanisms of anti-tumor action of corynebacterium parvum. I. Potential tumor-specific immunity and its therapeutic limitations. J Exp. Med. 154, 609–620.PubMedCrossRefGoogle Scholar
  20. 20.
    Oettgen, H F.and Old, L.J (1991) The History of Cancer Immunotherapy (DeVita, V. T., Helman, S., Rosenberg, S. A., eds.), Lippincott, New York, pp, 87–199.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 1997

Authors and Affiliations

  • Zhihai Qin
    • 1
  • Thomas Blankenstein
    • 1
  1. 1.Max-Delbrück-Centrum for Molecular MedicineBerlin

Personalised recommendations